Fludarabin (FLU) has become standard frontline therapy for CLL. 1 The results of autologous stem cell transplantation (ASCT) in poor-risk patients have stimulated its frontline use. 2 The combination of FLU with cyclophosphamide (CY) appears to be very efficient, even leading to molecular remissions 3 which could be advantageous before PBSC collection. However, it was convincingly documented that FLU impairs PBSC mobilization. 4, 5 This could decrease the proportion of patients who can proceed to ASCT, 6 as well as increase the morbidity and cost of ASCT. The ability to harvest sufficient graft is thus very important in CLL patients treated with FLU (7CY), who have failed the first ('standard') mobilization. However, studies investigating the various remobilization policies are limited in this setting. We examined the mobilizing efficiency of high-dose G-CSF alone in CLL patients who had previously failed to mobilize after standard chemotherapy þ G-CSF.
Since 1998, all patients in our department with poor risk CLL have entered a study in which they were treated upfront according to the following protocol: FLU 25 mg/ m 2 þ CY 250 mg/m 2 once daily for 3 days monthly until haematological remission, and thereafter two additional FLU-CY cycles. Patients then proceeded to PBSC mobilization that consisted of CY 3 g/m 2 þ G-CSF 5 mg/kg started at least 4 weeks after completion of FLU-CY, provided that blood counts had recovered. The aim was to harvest at least 2 Â 10 6 CD34 þ cells/kg bw with the threshold for the start of leukapheresis (LP) of 410 CD34 þ cells/ml. If successful (X2 Â 10 6 CD34 cells/kg harvested), patients proceeded directly to ASCT. From 1998, 56 patients completed the protocol, 23 (41%) of them underwent ASCT. In 33 (59%) patients mobilization failed and they were regarded as poor mobilizers. In all, 11 of these patients proceeded to a second mobilization attempt using G-CSF alone (filgrastim, Roche, CH) in doses of 20-25 mg/kg/day s.c. (high-dose G-CSF (HD G-CSF)) divided into two daily doses. The median age was 56 years (range 41-65); all had received at least four FLU-CY courses (median 5, range 4-6) with good response according to NCI criteria 7 (5 Â nPR, 6 Â CR). The response was sustained in all patients at remobilization. With the exception of one patient who underwent one LP with insufficient yield (0.69 Â 10 6 CD34 þ cells/kg), all have failed to reach the threshold for initiating LP during the first mobilization.
HD G-CSF was given during steady-state haematopoiesis after a median of 36 weeks (range 20-60) from the last FLU-CY course and 28 weeks (range 12-54) from the first mobilization. Filgrastim was given for 6 consecutive days and CD34 þ cells were measured from day 4 through 6. LP was initiated when circulating CD34 þ cells exceeded 10/ml. This policy resulted in total to 33 CD34 þ quantifications and relevant mobilization data are detailed in Table 1 . All patients had platelet counts above 150 Â 10 9 /l before and during G-CSF administration. Only three patients achieved a CD34 þ cell number X10 CD34 þ /ml, unfortunately only for 1 day. The values were 10 (fifth day), 11 (fourth day) and 15 (fifth day) CD34 þ cells/ml, and therefore only three LP were performed on these patients, generally with insufficient yields (Table 1 ). In one patient with an insufficient yield after the first mobilization (0.69 Â 10 6 CD34 þ cells/kg, see above), LP was started despite the low CD34 þ count (4/ml) in an unsuccessful attempt to complement the graft ( Table 1) . As can be seen from the table, the differences in mobilizing efficiency 
-test).
There is increasing evidence that FLU negatively affects PBSC mobilization and this effect seems to be durable and resistant to different mobilizing regimens. [4] [5] [6] The high rate of primary mobilization failures in the whole study group supports this presumption. The rationale for our remobilization strategy was the reported dose-dependent G-CSF efficacy in PBSC mobilization [8] [9] [10] and avoidance of toxicity of mobilizing chemotherapy. Kobbe et al 8 noted that the higher G-CSF dose was associated with higher levels of CD34 þ cells and a higher percentage of successful collections. However, he used G-CSF alone for both mobilization courses, and patients were not treated with FLU. Similarly, Lie et al 9 demonstrated a dose-dependent response of PBSC mobilization by G-CSF when used in combination with chemotherapy. Our results do not support this assumption in FLU-treated CLL patients. Rather, it accords with data recording mobilizing inefficiency of G-CSF alone in this setting. Tournilhac et al 6 reported a series of 38 CLL patients treated similarly, who were mobilized with filgrastim 10 mg/kg/day, and only 16% achieved the target of 2 Â 10 6 CD34 þ cells/kg bw and repeated mobilizations using the same procedure were likewise effective. A similar inefficiency of G-CSF alone in standard doses (5 mg/kg) was observed by Montillo et al, 10 eight out of 10 CLL patients treated upfront with FLU and Campath-1H failed to mobilize. Furthermore, increasing the dose of G-CSF to 10 mg proved to be an unsuccessful measure. There are no data to support that a longer interval from the last FLU to mobilization could enhance G-CSF-mobilizing efficiency. Our intervals were about 6 months and the experience of others, with a longer distance between FLU and mobilization, were similar. 6 Rather, by extending the intervals, we may lose the opportunity to obtain the graft during maximum response, that is, with minimum contamination. We conclude that G-CSF alone, regardless of the dose and interval from treatment, is an inadequate mobilizing technique in CLL patients treated with FLU. More potent mobilizing tools, probably adding innovative chemotherapy regimens to G-CSF, are needed and there are data illustrating the efficiency of, for example, ara-c in this setting. 10 Moreover, all trials incorporating FLU-CY and ASCT should take into account the longterm impairment of PBPC collection in a large proportion of patients. 
